Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

Author： Ellis Kyle J   Stouffer George A   McLeod Howard L   Lee Craig R  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.11, 2009-11, pp. : 1799-1817

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Aspirin + clopidogrel superior for platelet inhibition

By  

Inpharma, Vol. 1, Iss. 1529, 2006-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Clopidogrel + statins: effects on platelet inhibition

By  

Inpharma, Vol. 1, Iss. 1416, 2003-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA

By Lesko Lawrence J   Zineh Issam  

Pharmacogenomics, Vol. 11, Iss. 4, 2010-04 ,pp. : 507-512

Future Medicine

Access to resources Recommend Favorite

Carbamazepine, HLA-B*1502 and risk of Stevens––Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations

By Ferrell P Brent   McLeod Howard L  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1543-1546

Future Medicine

Access to resources Recommend Favorite

Inhibition of Platelet Activation by Clopidogrel Prevents Hypertension-Induced Cardiac Inflammation and Fibrosis

By Jia Li-Xin   Qi Guan-Ming   Liu Ou   Li Tao-Tao   Yang Min   Cui Wei   Zhang Wen-Mei   Qi Yong-Fen   Du Jie  

Cardiovascular Drugs and Therapy, Vol. 27, Iss. 6, 2013-12 ,pp. : 521-530

Springer Publishing Company

Access to resources Recommend Favorite